Search results
Results from the WOW.Com Content Network
Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said. ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
Merck & Co. (NYSE: MRK), a pharmaceutical giant known for its cancer immunotherapy drug Keytruda, has seen its stock surge 16.8% year-to-date. This impressive run follows aggressive buying by a ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. ... -Merck & Co raised its full-year revenue forecast on Tuesday as ...